Table 3.
Risk of Any Cardiac Admission and Specific Types of Admissions During or Following Trastuzumab Therapy
| Variable | Any Cardiac Admission |
Heart Failure/Cardiomyopathy Admission |
Other Cardiac Admission |
||||||
|---|---|---|---|---|---|---|---|---|---|
| % | OR* | 95% CI* | % | OR* | 95% CI* | % | OR* | 95% CI* | |
| Cardiac admission during treatment + 30 days (N = 2,028)† | 3.6 | 1.2 | 2.4 | ||||||
| Completed trastuzumab | |||||||||
| No (n = 372) | 8.1 | 1.00 | 4.0 | 1.00 | 4.0 | 1.00 | |||
| Yes (n = 1,656) | 2.6 | 0.32 | 0.21 to 0.49 | < 1.5‡ | 0.14 | 0.09 to 0.23 | 2.1 | 0.57 | 0.31 to 1.02 |
| Cardiac admission in the year following the last trastuzumab dose (N = 2,028)§ | 4.0 | 1.7 | 2.5 | ||||||
| Completed trastuzumab | |||||||||
| No (n = 372) | 11.6 | 1.00 | 6.7 | 1.00 | 5.4 | 1.00 | |||
| Yes (n = 1,656) | 2.3 | 0.22 | 0.12 to 0.41 | < 1.5‡ | 0.09 | 0.02 to 0.37 | 1.8 | 0.36 | 0.18 to 0.71 |
| Hospitalized during trastuzumab treatment | |||||||||
| Yes (n = 73) | 50.7 | 1.0 | 20.6 | 1.00 | 34.3 | 1.00 | |||
| No (n = 1,955) | 2.3 | 45.9 | 22.7 to 93.2 | 1.0 | 334.9 | 43.5 to 2,575.75 | 1.3 | 94.40 | 36.77 to 242.36 |
Abbreviation: OR, odds ratio.
Adjusting by age, race/ethnicity, comorbidity, trastuzumab initiation year, median household income, percent who graduated from high school, marital status, location of residence, and prior cardiac admission (yes or no). Patients with prior cardiac admissions and higher comorbidity were more likely to have a cardiac admission in both periods.
Calculated from first day of trastuzumab treatment until 30 days after the last trastuzumab claim. During treatment + 30 days after the last trastuzumab claim, 73 patients had 84 hospital admissions for cardiac events. The reasons for admissions (heart failure/cardiomyopathy v other cardiac admission) do not add up to 84 admissions because there were patients who were admitted for the same reason more than one time.
Exact proportion was not provided because of small cell sizes.
Calculated until 365 days after last trastuzumab claim. In the year after the last trastuzumab claim, 81 patients had 101 hospital admissions for cardiac events. The reasons for admissions (heart failure/cardiomyopathy v other cardiac admission) do not add up to 101 admissions because there were patients who were admitted for the same reason more than one time.